Carrier Screening
Reproductive health genetic carrier screening services
Service · OtherCompany source
Company profile
About Fulgent Genetics
Fulgent Genetics is a premier, full-service genomic testing company founded in 2011 and built around a foundational next-generation sequencing (NGS) technology platform. The company has evolved into a comprehensive precision medicine organization focused on transforming patient care across multiple therapeutic areas including oncology, anatomic pathology, infectious diseases, rare diseases, and reproductive health. Fulgent offers an unrivaled catalog of genetic testing options, including over 18,000 single gene tests, 900+ rare disease panels, whole genome sequencing, whole genome copy number variation analysis, mitochondrial sequencing, and customizable NGS panels. The company was the first clinical laboratory in the United States to offer copy number variation detection using NGS technology. All testing is performed at their six CLIA-certified and CAP-accredited laboratories across the United States, with all data analysis conducted on private servers. Recently, Fulgent has expanded beyond diagnostics into therapeutic development, creating drug candidates for treating cancers using a novel nanoencapsulation and targeted therapy platform. The company has also completed strategic acquisitions including Bako Diagnostics and StrataDx to strengthen its capabilities. Through flexible testing options, best-in-class service, and a commitment to innovation, Fulgent aims to redefine how medicine is managed for patients and clinicians while becoming a fully integrated precision medicine company.
Company description Fulgent Genetics official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at Fulgent Genetics?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- carrier screening conditions
- hereditary cancer
- infectious diseases
- oncology
- prenatal conditions
- rare diseases
- reproductive health conditions
Who it serves
- Clinicians
- Healthcare Providers
- Physicians
Deployment & integration
Other deployment with recorded integration context.
Geographic context
MarketsUnited States
Company sourceOfficial website
Company milestones
Platform expansion
Completed acquisition of Bako Diagnostics and StrataDx. Expanded into therapeutic development with novel nanoencapsulation and targeted therapy platform for cancer treatment.
Partnerships
Recorded partners
- Bako Diagnostics (acquired)
- StrataDx (acquired)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
Custom NGS Panels
Fully customizable genetic testing panels from 18,000+ available genes
Service · OtherCompany source
Disease Panels
Over 800 pre-designed genetic testing panels for rare diseases
Service · OtherCompany source
Hereditary Cancer Testing
Comprehensive genetic testing for hereditary cancer risk assessment
Service · OtherCompany source
Known Mutation Testing
Targeted testing for previously identified genetic mutations
Service · OtherCompany source
Mitochondrial Sequencing
Specialized sequencing for mitochondrial genome analysis
Service · OtherCompany source
Oncology Testing
Comprehensive genetic testing for cancer diagnosis and treatment
Service · OtherCompany source
Prenatal Testing
Genetic testing services for prenatal diagnosis and screening
Service · OtherCompany source
Single Gene Tests
Comprehensive single gene testing covering over 18,000 genes
Service · OtherCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Rad51 determines pathway usage in post-replication repair.Nature communications · Jan 10, 2026
Barnaculate Carcinoma in Four Patients: Verrucoid Squamous Cell Carcinoma Subtype with TERT and HRAS Oncogenic Variants.Head and neck pathology · Jan 5, 2026
BRAF V600E Mutation Has Variable Tumor-Specific Effects on Expression of MAPK Pathway Genes That Could Affect Patient Outcome.International journal of molecular sciences · Aug 16, 2025
A primer on regulation of laboratory-developed testing procedures: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG).Genetics in medicine : official journal of the American College of Medical Genetics · Jun 1, 2025
Advances in Prenatal Cell-Free DNA Screening for Dominant Monogenic Conditions: A Review of Current Progress and Future Directions in Clinical Implementation.Prenatal diagnosis · Apr 1, 2025
Heterozygous loss of function variants in IFT140 are associated with polycystic kidney disease.American journal of medical genetics. Part A · Dec 1, 2024
Clinical validation
Clinical-trial records
Parkinson's Foundation PD GENEration Genetic RegistryNCT04994015 · Sponsor · RECRUITING
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Fulgent Genetics
Recent articles published on Fulgent Genetics's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.